BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30214063)

  • 21. EVI1 oncoprotein expression and CtBP1-association oscillate through the cell cycle.
    Paredes R; Schneider M; Pearson S; Teng HY; Kelly JR; Pierce A; Somervaille TCP; Whetton AD; Meyer S
    Mol Biol Rep; 2020 Oct; 47(10):8293-8300. PubMed ID: 32979164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.
    Maicas M; Vázquez I; Alis R; Marcotegui N; Urquiza L; Cortés-Lavaud X; Cristóbal I; García-Sánchez MA; Odero MD
    Biochim Biophys Acta Gene Regul Mech; 2017 Jun; 1860(6):721-729. PubMed ID: 28391050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted suppression of EVI1 oncogene expression by sequence-specific pyrrole-imidazole polyamide.
    Syed J; Pandian GN; Sato S; Taniguchi J; Chandran A; Hashiya K; Bando T; Sugiyama H
    Chem Biol; 2014 Oct; 21(10):1370-1380. PubMed ID: 25219965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imbalanced expression of polycistronic miRNA in acute myeloid leukemia.
    Kotaki R; Higuchi H; Ogiya D; Katahira Y; Kurosaki N; Yukihira N; Ogata J; Yamamoto H; Mohamad Alba S; Azhim A; Kitajima T; Inoue S; Morishita K; Ono K; Koyama-Nasu R; Kotani A
    Int J Hematol; 2017 Dec; 106(6):811-819. PubMed ID: 28831750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment.
    Masamoto Y; Chiba A; Mizuno H; Hino T; Hayashida H; Sato T; Bando M; Shirahige K; Kurokawa M
    Blood Adv; 2023 Apr; 7(8):1577-1593. PubMed ID: 36269819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a novel E-box binding pyrrole-imidazole polyamide inhibiting MYC-driven cell proliferation.
    Mishra R; Watanabe T; Kimura MT; Koshikawa N; Ikeda M; Uekusa S; Kawashima H; Wang X; Igarashi J; Choudhury D; Grandori C; Kemp CJ; Ohira M; Verma NK; Kobayashi Y; Takeuchi J; Koshinaga T; Nemoto N; Fukuda N; Soma M; Kusafuka T; Fujiwara K; Nagase H
    Cancer Sci; 2015 Apr; 106(4):421-9. PubMed ID: 25611295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogene
    Pastoors D; Havermans M; Mulet-Lazaro R; Brian D; Noort W; Grasel J; Hoogenboezem R; Smeenk L; Demmers JAA; Milsom MD; Enver T; Groen RWJ; Bindels E; Delwel R
    Sci Adv; 2024 May; 10(20):eadk9076. PubMed ID: 38748792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia.
    Yamakawa N; Kaneda K; Saito Y; Ichihara E; Morishita K
    PLoS One; 2012; 7(1):e30706. PubMed ID: 22295105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
    Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
    J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
    Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
    Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EVI1 drives leukemogenesis through aberrant ERG activation.
    Schmoellerl J; Barbosa IAM; Minnich M; Andersch F; Smeenk L; Havermans M; Eder T; Neumann T; Jude J; Fellner M; Ebert A; Steininger M; Delwel R; Grebien F; Zuber J
    Blood; 2023 Feb; 141(5):453-466. PubMed ID: 36095844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and anti-cancer activity of pyrrole-imidazole polyamides through target-downregulation of c-kit gene expression.
    Zhang M; Liang J; Jiang SK; Xu L; Wu YL; Awadasseid A; Zhao XY; Xiong XQ; Sugiyama H; Zhang W
    Eur J Med Chem; 2020 Dec; 207():112704. PubMed ID: 32866755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EVI1 protein interaction dynamics: Targetable for therapeutic intervention?
    Paredes R; Doleschall N; Connors K; Geary B; Meyer S
    Exp Hematol; 2022 Mar; 107():1-8. PubMed ID: 34958895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
    Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G
    Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML.
    Cuenco GM; Nucifora G; Ren R
    Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1760-5. PubMed ID: 10677531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal time-points for detecting expression levels of BAALC, EVI1, and WT1 genes in patients with acute myeloid leukemia: a meta-analysis.
    Yuen KY; Lin XY; Zhou YZ; Luo H; Liu Y; Xu LH
    Hematology; 2021 Dec; 26(1):995-1006. PubMed ID: 34871539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.
    Nii T; Prabhu VV; Ruvolo V; Madhukar N; Zhao R; Mu H; Heese L; Nishida Y; Kojima K; Garnett MJ; McDermott U; Benes CH; Charter N; Deacon S; Elemento O; Allen JE; Oster W; Stogniew M; Ishizawa J; Andreeff M
    Leukemia; 2019 Dec; 33(12):2805-2816. PubMed ID: 31127149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1(high) leukemia cells.
    Ichihara E; Kaneda K; Saito Y; Yamakawa N; Morishita K
    Biochem Biophys Res Commun; 2011 Dec; 416(3-4):239-45. PubMed ID: 22033412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evi1 upregulates Fbp1 and supports progression of acute myeloid leukemia through pentose phosphate pathway activation.
    Mizuno H; Koya J; Masamoto Y; Kagoya Y; Kurokawa M
    Cancer Sci; 2021 Oct; 112(10):4112-4126. PubMed ID: 34363719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
    Fenouille N; Bassil CF; Ben-Sahra I; Benajiba L; Alexe G; Ramos A; Pikman Y; Conway AS; Burgess MR; Li Q; Luciano F; Auberger P; Galinsky I; DeAngelo DJ; Stone RM; Zhang Y; Perkins AS; Shannon K; Hemann MT; Puissant A; Stegmaier K
    Nat Med; 2017 Mar; 23(3):301-313. PubMed ID: 28191887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.